Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The hepatitis A vaccine, live attenuated (H2 strain) is a viral vaccine used for the active prevention of hepatitis A virus (HAV) infection. It contains the H2 strain of HAV, which has been attenuated through serial passage in human diploid cells to reduce pathogenicity while maintaining high immunogenicity. Upon administration, the vaccine replicates limitedly in the host, mimicking a natural infection to stimulate a robust and long-lasting immune response, including the production of neutralizing antibodies. It is commonly supplied as a lyophilized (freeze-dried) powder for injection. Mellowhope Pharmaceutical is a key exporter of this approved vaccine, which is widely used in public health settings to control hepatitis A outbreaks and provide routine immunization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hepatitis a vaccine, live attenuated (h2 strain).